|
市場調查報告書
癌症疫苗以及循環腫瘤細胞（CTC）市場：2011年
Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
|
癌症疫苗以及循環腫瘤細胞（CTC）市場：2011年 是由出版商Select Biosciences, Ltd.在2011年01月所出版的。
這份英文市場調查報告書包含139 Pages 價格從美金2692起跳。
本報告，分析循環腫瘤細胞（CTC）市場的技術以及市場環境，並介紹CTC的特徵、檢測、分析方式等，由下列摘要形式闡述。
第1章 報告摘要
第2章 癌症疫苗：技術以及市場分析
- 癌症免疫療法概要
- 癌症免疫療法的歷史里程碑
- 癌症疫苗的分類
- 腫瘤相關抗原
- 腫瘤特異性抗原
- 抗癌疫苗策略
- 失敗的治療用癌症疫苗候補
- 提高癌症疫苗成功率的策略
- 癌症疫苗市場概要
- 美國FDA認可的癌症疫苗：預防以及治療
- 在各國已被認可的癌症疫苗
- 第3階段臨床試驗的癌症疫苗產品線
- 早期（第1階段、第2階段）產品線
- 前臨床試驗產品線
- 個別化疫苗
第3章 循環腫瘤細胞（CTC）：技術以及市場分析
- 轉移以及上皮細胞轉形成間葉細胞
- 何謂CTC
- CTC與DTC
- CTC的臨床適切性
- CTC的特徵
- CTC的檢測與診斷
- CTC的生物學
- CTC分析方式
- CTC濃縮、檢測、特性化方式
- CTC檢測的微流體裝置
- CTC分析的相關臨床試驗
附錄：調查方式
Abstract
This market report from Select Biosciences presents a comprehensive industry
analysis of the cancer vaccines space as well as that of the emerging
circulating tumor cells (CTCs) space. These two areas are evolving and
expanding driven by the greater emphasis on personalized medicine especially
in the cancer/oncology space.
Cancer vaccines can be generated using a number of different approaches and
this report describes these approaches vis-à-vis their advantages and
disadvantages and associated technical characteristics. Indeed, the
FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key
milestone in this space and a driver for R&D efforts forward. This report
presents the pre-clinical pipeline, early-stage clinical trial pipeline, and
the late-stage clinical pipeline for the cancer vaccines space. Also presented
are the failed vaccine candidates with a discussion about these failures and
how the industry can benefit via a deeper understanding of what components are
required for effective immune system activation in vivo and effective
vaccination - either preventative or therapeutic.
This report also examines the technology and market landscape for circulating
tumor cells (CTCs). There is currently much interest in CTCs as they may offer
a highly-sensitive biomarker for cancer detection via a minimally-invasive
route. The cancer research field is currently seeking to understand the role
of CTCs in metastases and in this vein this report is highly-useful in that it
frames the biology of CTCs, characteristics of CTCs, methodologies for CTC
enrichment, CTC detection, and analytical methods. This report also snapshots
the clinical trials being conducted currently involving CTCs.
Extensive Worldwide Technical and Market Analyses Presented in this Report:
- Classification and Characterization of Cancer Vaccines
- Various Approaches for the Generation of Cancer Vaccines
- Anti-Cancer Vaccination Strategies
- Tumor Associated Antigens (TAAs)
- Tumor Specific Antigens (TSAs)
- Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure
- Strategies to Improve Success of Cancer Vaccines
- US FDA-Approved Cancer Vaccines
- Therapeutic Cancer Vaccines Approved in Various Countries Around the World
- Cancer Vaccine Pipeline in Late-Stage Clinical Trials
- Cancer Vaccine Pipeline in Early-Stage Clinical Trials
- Pre-Clinical Cancer Vaccine Pipeline
- Personalized Cancer Vaccination Strategies
- Biology and Characteristics of CTCs
- Methodologies/Various Technologies for Enrichment, Detection, and
Characterization of CTCs
- More details of the scope of coverage of this industry report are found in
the Table of Contents (TOC) for the report
Table of Contents
Chapter I. Executive Overview
Chapter II. Cancer Vaccines: Technology & Market Analysis
- Cancer Immunotherapy Overview
- Historical Milestones in Cancer Immunotherapy
- Classification of Cancer Vaccines
- Tumor Associated Antigens (TAAs)
- Tumor Specific Antigens (TSAs)
- Anti-Cancer Vaccination Strategies
- Failed Therapeutic Cancer Vaccine Candidates
- Strategies to Improve Success of Cancer Vaccines
- Cancer Vaccines Market Overview
- US FDA-Approved Cancer Vaccines: Preventative & Therapeutic
- Therapeutic Cancer Vaccines Approved in Various Countries
- Cancer Vaccine Pipeline in Phase III Clinical Trials
- Early Stage (Phases I & II) Pipeline
- Pre-Clinical Pipeline
- Personalized Vaccines
Chapter III. Circulating Tumor Cells (CTCs): Technology & Market Analysis
- Metastasis and Epithelial-to-Mesenchymal Transition (EMT)
- What are CTCs?
- CTCs vs. DTCs
- Clinical Relevance of CTCs
- Characteristics of CTCs
- Detection and Diagnostics of CTCs
- Biology of CTCs
- CTC Analysis Methodologies
- CTC Enrichment, Detection, and Characterization Methods
- Microfluidic Devices for CTC Detection
- Clinical Trials Involving CTC Analysis
Appendix I. Research Methodology
|
